Skip to content
Pharma Observatory a Scientist.com platform

Gene

SEC31A

SEC31A is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (5), Target-disease associations (45), and 4 more evidence types, each linked to its source.

Ensembl ENSG00000138674 UniProt O94979 Matched to Ensembl and UniProt
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

FDA companion diagnostic assertions FDA companion diagnostic assertions 1 Assay-provider ledger Assay-provider ledger 5 Target-disease associations Target-disease associations 45 Vendor sourcing Vendor sourcing 5 Trial-cited literature Trial-cited literature 8 Protein variant mentions Protein variant mentions 1 Organizations publishing Organizations publishing 33 FDA companion diagnostic assertions FDA companion diagnostic assertions 1 Assay-provider ledger Assay-provider ledger 5 Target-disease associations Target-disease associations 45 Vendor sourcing Vendor sourcing 5 Trial-cited literature Trial-cited literature 8 Protein variant mentions Protein variant mentions 1 Organizations publishing Organizations publishing 33

Rows recorded per section (log scale)

5 sections measured, none recorded

FDA companion diagnostic

An FDA-cleared or approved companion diagnostic names this biomarker.

Get the SEC31A report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Evidence over time

Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention SEC31A. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.

Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.

SEC31A has 8 publication mentions across 4 years. That is too few to read as a trend, so the years are listed instead.

The yearly numbers
SEC31A per year, by evidence type, the most recent 10 years, newest first; the chart covers 1990 to 2023. The share is of the papers our biomarker dictionary matched that year, not of the literature at large, and a blank year is one our matched corpus does not cover at all.
Year Publication mentions Share of that year
2023 0 of 11,460 0.00%
2022 0 of 13,598 0.00%
2021 2 of 15,045 0.01%
2020 0 of 14,459 0.00%
2019 1 of 12,159 0.01%
2018 0 of 11,854 0.00%
2017 3 of 11,595 0.03%
2016 0 of 10,983 0.00%
2015 0 of 11,395 0.00%
2014 0 of 10,367 0.00%

Showing 10 of 34 years.

Start your 14-day trial Email me all 34 years as a PDF

FDA companion diagnostic assertions (1)

Shown in this order: most recent decision first.

FDA companion diagnostic assertions
Diagnostic Source biomarker wording Manufacturer Indication Decision date
Idylla CDx MSI Test SEC31A Biocartis US, Inc. Colorectal Cancer (CRC) 2025-08-15

Assay-provider ledger (5)

Shown in this order: most recent publication first.

Assay-provider ledger
Company Provider class Validation Papers Most recent publication
Biocartis Diagnostic provider Clinical validation 3 September 01, 2025
Agilent Technologies Reagent supplier Clinical validation 1 July 24, 2021
DAKO (Carpinteria, CA, USA) - IHC antibodies and Autostainer Link 48 platform Context dependent Clinical validation 1 July 24, 2021
Diatech Pharmacogenetics Diagnostic provider Clinical validation 1 July 24, 2021
Qiagen (Hilden, Germany) - Mini Amp DNA extraction kit Reagent supplier Clinical validation 1 July 24, 2021

Target-disease associations (45)

Shown in this order: fixed catalogue order, not ranked.

Target-disease associations
Disease Therapeutic area Source
HDL cholesterol change measurement measurement GWAS credible sets
IGF-1 measurement measurement GWAS credible sets
JT interval measurement GWAS credible sets
Kaya-Barakat-Masson syndrome genetic, familial or congenital disease Variant curation (ClinVar / EVA)
Red cell distribution width measurement GWAS credible sets

Showing 5 of 45 associations.

Start your 14-day trial Email me all 45 associations as a PDF

Vendor sourcing (5)

Shown in this order: alphabetical by organization.

Vendor sourcing
Organization Role Tier Evidence Citation
Ambry Genetics (United States) Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission The c.251A>G (p.D84G) alteration is located in exon 4 (coding exon 3) of the SEC31A gene. This alteration results from a A to G substitution at nucleotide po... View ClinVar record SCV003531142.3
DASA (Brazil) Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission NM_001077207.4(SEC31A):c.1835G>A (p.Arg612Gln) is a missense variant that results in the substitution of arginine with glutamine. This variant is rare in pop... View ClinVar record SCV007664056.2
Greenwood Genetic Center Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission PM2 View ClinVar record SCV002568310.1
Labcorp Holdings Inc. Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission Variant summary: SEC31A c.511A>G (p.Ile171Val) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools pred... View ClinVar record SCV004122250.1
Not resolved to an organization Diagnostics manufacturer FDA-authorized companion diagnosticFDA companion diagnostic authorization Microsatellite instability-High (MSI-H) View FDA device record

Trial-cited literature (8)

Shown in this order: newest first, then most cited.

Trial-cited literature
Publication Journal Year Citations
Emerging Roles of Impaired Autophagy in Fatty Liver Disease and Hepatocellular Carcinoma. International journal of hepatology 2021 39
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer biology & medicine 2021 26
The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration. Cell communication and signaling : CCS 2019 37
A molecular portrait of microsatellite instability across multiple cancers. Nature communications 2017 498
Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer discovery 2017 429

Showing 5 of 8 papers.

Start your 14-day trial Email me all 8 papers as a PDF

Protein variant mentions (1)

Shown in this order: alphabetical by variant.

Protein variant mentions
Variant Distinct papers Year range Sample papers
p.C458W 1 2015 PMID 25741868

Organizations publishing (33)

Shown in this order: most papers first.

Organizations publishing
Organization Type Papers Years
Chinese PLA General Hospital Hospital 1 2021
Dana-Farber Cancer Institute Other 1 2010
Duke University Academic 1 2010
Emory University School of Medicine Other 1 2017
Guy's and St Thomas' NHS Foundation Trust Hospital 1 2017

Showing 5 of 33 organizations.

Start your 14-day trial Email me all 33 organizations as a PDF

Where SEC31A appears

  • cancer or benign tumor
  • cardiovascular disease
  • endocrine system disease
  • genetic, familial or congenital disease
  • measurement
  • nervous system disease

43 diseases touched.

Not on this page

Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, trial mentions, human sample screening reference, and literature-extracted relations.

Browse all biomarker evidence pages